Clinical Cooperation Unit Nuclear Medicine 

Overview

The Clinical Cooperation Unit Nuclear Medicine is involved in multiple projects on topics such as the identification of new peptides with high affinity for tumor disease; the establishment of new endoradiotherapy approaches based on peptides and antibodies; the use of scaffold proteins for the development of new peptidic tracers with improved stability and affinity; the development of alternate panning strategies using recombinant proteins, membrane fractions and cells; the design of combination therapy with endoradiotherapy and chemo-, immuno- or radiation therapy; and the establishment of new treatments for non-iodine-concentrating thyroid carcinoma.

Significant accomplishments of the past 5 years

The CCU Nuclear Medicine has:

• evaluated 68Ga-DOTATOC-PET for the diagnosis and therapy planning of meningeomas and neuroendocrine tumors (Eur J Nucl Med Mol Imaging 2006, 33:460-6; Clin Cancer Res 2010, 16:2899-905).
• performed the preclinical and clinical evaluation of 68Ga-Bombesin-PET (J Nucl Med 2007, 48:1245-50).
• modified radioisotope accumulation by gene transfer (sodium iodide symporter, norepinephrine transporter) (J Nucl Med 2005, 46:831-9).
• designed tissue- or tumor-specific viral vectors using specific promoter/enhancer elements.
• performed gene therapy with suicide and anti-angiogenic genes and characterized its effects (Eur J Nucl Med Mol Imaging 2007, 34:2011-23).
• established the Phage Display and Ribosome Display techniques, and identified peptides with high affinity for prostate, thyroid and head and neck cancers (J Nucl Med 2009, 50:426-34).
• developed techniques for peptide synthesis and modification (J Nucl Med 2007, 48:965-72).

5 most significant publications of the past 5 years

Zitzmann S, Kramer S, Mier W, Hebling U, Altmann A, Rother A, Berndorff D, Eisenhut M, Haberkorn U: Identification and Evaluation of a New Tumor Cell-Binding Peptide, FROP-1. J Nucl Med 2007, 48:965-72

Mier W, Zitzmann S, Kramer S, Reed J, Knapp EM, Altmann A, Eisenhut M, Haberkorn U: Influence of Chelate Conjugation on a Newly Identified Tumor-Targeting Peptide. J Nucl Med 2007, 48:1545-52

Haberkorn U, Hoffend J, Schmidt K, Altmann A, Bonaterra GA, Dimitrakopoulou-Strauss A, Strauss LG, Eisenhut M, Kinscherf R: Changes in glucose metabolism and gene expression after transfer of anti-angiogenic genes in rat hepatoma. Eur J Nucl Med Mol Imaging 2007, 34:2011-23

Petersen J, Dandri M, Mier W, Lütgehetmann M, Volz, T, Weizsäcker v F, Haberkorn U, Fischer L, Pollok JM, Erbes B, Seitz S, Urban S: Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008, 26:335-41

Nothelfer EM, Zitzmann-Kolbe S, Garcia-Boy R, Krämer S, Herold-Mende C, Altmann A, Eisenhut M, Mier W, Haberkorn U: Identification and Characterization of a Peptide with Affinity to Head and Neck cancer. J Nucl Med 2009, 50:426-34

Contact

Prof. Dr. Uwe Haberkorn
German Cancer Research Center (DKFZ)
Imaging and Radiooncology
Im Neuenheimer Feld 280
69120 Heidelberg

Tel: 06221 42 2477
Fax:06221 42 2510
u.haberkorn@dkfz.de

and
Heidelberg University Hospital
Dept. of Nuclear Medicine
Im Neuenheimer Feld 400
69120 Heidelberg
Tel: 06221 567731
Fax: 06221 565473
Uwe.Haberkorn@med.uni-heidelberg.de

News

Felix Burda Awards was granted to DKFZ and NCT for engagement in the colon cancer prevention 

Donate

Cancer Research needs your support